OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gordon on Managing Toxicities Associated With Liso-Cel in MCL

November 19th 2024

Leo I. Gordon, MD, discusses toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Dr Sharma on the Impact of Frontline Treatment Advances in Advanced Bladder Cancer

November 19th 2024

Janaki Neela Sharma, MD, discusses the implications of treatment advances in the front line for patients with advanced bladder cancer.

Dr Kim on the CARES-310 Study of Rivoceranib Plus Camrelizumab in First-Line HCC

November 19th 2024

Richard Kim, MD, discusses the phase 3 CARES-310 trial evaluating rivoceranib plus camrelizumab in first-line hepatocellular carcinoma.

Dr Sharma on the CheckMate 901 Study in Advanced Urothelial Cancer

November 18th 2024

Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.

Dr Rimm on the Utility and Shortcomings of HER2 IHC Testing in Breast Cancer

November 18th 2024

David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

November 15th 2024

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

November 15th 2024

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Awan on Treatment Considerations With Pirtobrutinib in Hematologic Malignancies

November 15th 2024

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Dr Lin on the Safety of T-DXd for HER2+ Breast Cancer With/Without Brain Metastases

November 15th 2024

Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.

Dr DeAngelo on Non-Chemotherapy Treatment Options in CLL

November 15th 2024

Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

November 14th 2024

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14th 2024

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors

November 13th 2024

Victor Moreno, MD, PhD, discusses insights into the pharmacodynamic activity of CLN-619 for patients with advanced solid tumors.

Dr Biachi on the Evolving Role for Surgery in CRC

November 12th 2024

Tiago Biachi, MD, PhD, discusses the evolving role for surgery in colorectal cancer.

Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC

November 12th 2024

Nicolas Girard, MD, discusses both de novo and acquired resistance alterations in HER2-altered non–small cell lung cancer.

Dr Jabbour on the FDA Approval of Obe-Cel for Adult Patients With Relapsed or Refractory B-cell Precursor ALL

November 11th 2024

Dr DeAngelo on the Integration of JAK Inhibitors in Myelofibrosis Management

November 11th 2024

Daniel DeAngelo, MD, discusses the integration of JAK inhibitors into clinical practice for patients with myelofibrosis.

Dr Sborov on CAR T-Cell Therapy–Specific Long-Term Treatment Effects in Myeloma

November 11th 2024

Douglas W. Sborov, MD, MS, discusses long-term treatment outcomes for patients with myeloma who received CAR T-cell therapy vs another treatment option.

Dr Dimopoulos on Efficacy Findings From the DREAMM-8 Trial in Multiple Myeloma

November 9th 2024

Meletios Dimopoulos, MD, discusses the design of and findings from the DREAMM-8 trial investigating BPd in patients with multiple myeloma.

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC

November 9th 2024

Adam E. Singer, MD, PhD, discusses currently available combination treatment regimens for the first-line treatment of patients with renal cell carcinoma.